Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146079 | 0.89 | POLB (0.49) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL26273832 | 0.89 | POLB (0.49) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL14618095 | 0.89 | LGALS3 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL14586558 | 0.87 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL16256917 | 0.86 | LGALS3 (0.53) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL14618096 | 0.85 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL16256916 | 0.81 | LGALS9 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL5695036 | 0.81 | PTPN1 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL5695045 | 0.81 | PTPN1 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 | |
| SCHEMBL5695029 | 0.81 | PTPN1 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037770-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | GERON CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037770-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | RNGTT, MTAP, TYMP | LGALS9 2991/4885LGALS1 3359/4885LGALS3 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.